While the British drugmaker did not comment on the tentative timeline when the trial would resume, AstraZeneca Plc Chief Executive Officer, Pascal Soriot said that the Oxford coronavirus could still be made available by the end of 2020.

“I still think we are on track for having a set of data that we would submit before the end of the year for regulatory approval,” Pascal said at a media event.

He added that depending on “how fast the regulators move, they could still have a vaccine by the end of this year, early next year.”



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *